Solventum's second-quarter profit falls 70% on higher expenses
Aug 8 (Reuters) -3M spin-off Solventum's SOLV.N second-quarter profit fell more than 70% on Thursday, hurt by limited sales growth of its wound care and surgical sterilization products and higher expenses, as it navigates functioning as a newly independent company.
These were Solventum's first financial results as an independent company. Its first-quarter results were prepared on a "carve-out" basis from 3M's healthcare business.
In its first-quarter earnings, the company had warned that it expected stand-up functional expenses to increase for the rest of the year.
Total operating expenses rose about 11%, to $1.84 billion, for the second quarter.
Minnesota-based Solventum is one of the largest providers of sterilization devices, wound dressings, medical tape and other hospital consumables used by healthcare facilities.
Its net income fell over 70% in the reported quarter to $89 million, or 51 cents per share, from $321 million, or $1.86 per share, a year earlier.
Total net sales were $2.08 billion, almost flat compared to last year.
More than half of total sales in the second quarter came from Solventum's MedSurg business, which provides wound dressings and surgical equipment.
The medical equipment maker raised the per-share range of its current-year adjusted profit forecast to between $6.30 and $6.50, from its earlier range of $6.10 per share to $6.40 per share.
"We are starting from a solid foundation and remain focused on addressing historical underperformance and spin-related topics to unlock significant value creation over time," CEO Bryan Hanson said.
The company now expects full-year organic sales to be flat to up 1%. Its earlier organic sales forecast was flat to down 2%.
On an adjusted basis, Solventum earned $1.56 per share for the quarter ended June 30.
Reporting by Vaibhav Sadhamta; Editing by Pooja Desai
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
